Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

DISEASE CHARACTERISTICS: * Radiologically or histologically confirmed hepatocellular carcinoma * Stage III or IV primary disease * Recurrent, unresectable, or metastatic disease meeting any of the following criteria: * Pancreatic cancer that underwent prior surgical resection and progressed with recurrent metastatic disease to the liver * Gastric, colon, breast, or ovarian cancer or melanoma with metastatic disease to the liver * Primary or recurrent disease that cannot be surgically resected leaving the patient disease-free * Radiologically measurable disease * Ineligible for liver transplantation according to University of San Francisco listing criteria: * Single lesion \> 6.5 cm * Three or more tumors \> 4.5 cm * Cumulative tumor diameter \> 8 cm PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% * ANC ≥ 1,500/mm³ * Platelets ≥ 75,000/mm³ * Creatinine ≤ 1.7 mg/dL * Total bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 3 times the upper limit of normal * INR \< 1.5 * LVEF ≥ 50% * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No serious concurrent infection or medical illness that would render the protocol treatment unsafe * LVEF ≥ 50% PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No concurrent steroids